Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02872311
Other study ID # MCL10416
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date September 2018

Study information

Verified date December 2019
Source Marshfield Clinic Research Foundation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, randomized trial in up to 210 adults aged 65-74 years to evaluate the immune response to consecutive influenza vaccination across 2 seasons. Participants will be randomized to receive 1 of 3 licensed and recommended vaccines in the first year; 2 arms will receive the same vaccination in the second year and the third arm will be randomized again to 1 of 3 licensed vaccines. All participants will have pre and post-vaccination serum blood draws for a total of 6 draws over 18 months.


Recruitment information / eligibility

Status Completed
Enrollment 179
Est. completion date September 2018
Est. primary completion date April 2018
Accepts healthy volunteers No
Gender All
Age group 65 Years to 74 Years
Eligibility Inclusion Criteria:

- Age 65-74 years at the time of study enrollment and are ambulatory and live in selected Wisconsin community or surrounding communities.

- Willing and able to give informed consent prior to study enrollment

- Able to comply with study requirements.

Exclusion Criteria:

- Prior receipt of 2016-17 influenza vaccine

- Current participation in another clinical trial

- Presence of a contraindication to influenza vaccine

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
High Dose Influenza vaccine
Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
Adjuvanted Influenza vaccine
Licensed and FDA approved FluAd vaccine to be administered to study participants
Standard Dose Influenza vaccine
Licensed and FDA approved Fluvirin vaccine to be administered to study participants
Recombinant Influenza vaccine
Licensed and FDA approved FluBlok vaccine to be administered to study participants

Locations

Country Name City State
United States Marshfield Clinic - Marshfield Center Marshfield Wisconsin

Sponsors (2)

Lead Sponsor Collaborator
Marshfield Clinic Research Foundation Centers for Disease Control and Prevention

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary HI Titers, HD vs. AD, Yr 1 Day 28 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2016-17 Year 1, Day 28 post vaccination
Primary HI Titers, HD vs. AD, Yr 1 Day 182 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2016-17 Year 1, Day 182 post vaccination
Primary HI Titers, HD vs. AD, Yr 1 Day 365 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 365 days post vaccination 2016-17 Year 1, Day 365 post vaccination
Primary HI Titers, HD vs. AD, Yr 2 Day 28 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 28 days post vaccination 2017-18 Year 2, Day 28 post vaccination
Primary HI Titers, HD vs. AD, Yr 2 Day 182 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses for high dose and adjuvanted vaccine recipients at 182 days post vaccination 2017-18 Year 2, Day 182 post vaccination
Secondary HI Response by Prior Season Vaccination, Yr 1, Day 28 Post Vaccination Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 28 days post vaccination, 2016-17 Year 1, Day 28 post vaccination
Secondary HI Response by Prior Season Vaccination, Yr 1, Day 182 Post Vaccination Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 182 days post vaccination, 2016-17 Year 1, Day 182 post vaccination
Secondary HI Response by Prior Season Vaccination, Yr 1, Day 365 Post Vaccination Hemagglutination inhibition (HI) Titers by prior season (2015-16) vaccination status among adjuvant and high dose vaccine recipients 365 days post vaccination, 2016-17 Year 1, Day 365 post vaccination
Secondary MN Titers, HD vs. AD, Year 1, Day 28 Post Vaccination Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2016-17 Year 1, Day 28 post vaccination
Secondary MN Titers, HD vs. AD, Year 1, Day 182 Post Vaccination Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 182 days post vaccination, 2016-17 Year 1, Day 182 post vaccination
Secondary MN Titers, HD vs. AD, Year 1, Day 365 Post Vaccination Microneutralization antibody titers to vaccine and drifted viruses among high dose and adjuvanted vaccine recipients 365 days post vaccination, 2016-17 Year 1, Day 365 post vaccination
Secondary MN Titers (A/Hong Kong (Siat Cell)), HD vs. AD, Year 2, Day 28 Post Vaccination Microneutralization antibody titers to vaccine virus (A/Hong Kong (siat cell) among high dose and adjuvanted vaccine recipients 28 days post vaccination, 2017-18 Year 2, Day 28 post vaccination
Secondary HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 28 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 28 days post vaccination 2017-18 Year 2, Day 28 post vaccination
Secondary HI Titers, HD vs. AD vs. RIV With Prior Season Standard (IIV) Dose, Year 2, Day 182 Post Vaccination Hemagglutination Inhibition (HI) titers to vaccine viruses among adjuvant, high dose and recombinant recipients with prior season standard dose vaccine at 182 days post vaccination 2017-18 Year 2, Day 182 post vaccination
Secondary HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 28 Post Vaccination Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 28 days after vaccination, 2017-18 Year 2, Day 28 post vaccination
Secondary HI Titers, IIV+AD or HD vs. Sequential AD or HD, Year 2, Day 182 Post Vaccination Hemagglutination inhibition (HI) titers among HD and AD based on prior season vaccination (standard or sequential same vaccination) at 182 days after vaccination, 2017-18 Year 2, Day 182 post vaccination
Secondary Number of Participants With Vaccine Failure, Year 1 Number of Participants with Vaccine Failure in Year 1 by vaccine type Year 1, Post season
Secondary Number of Participants With Vaccine Failure, Year 2 Number of Participants with Vaccine Failure in Year 2 by two-year vaccine history Year 2, Post season
See also
  Status Clinical Trial Phase
Recruiting NCT05515263 - Snack Foods and Their Impact on the Immune Response Following Influenza Vaccination N/A
Completed NCT01861613 - Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Phase 4
Completed NCT03982069 - Immunologic Response to FluMist vs. Flucelvax Phase 4
Recruiting NCT06041867 - Agaricus Bisporus and Influenza Vaccination Response N/A
Completed NCT03614975 - Immunologic Response to Influenza Vaccination in Children and Adolescents Phase 4
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03875703 - Post-Vaccination Biological Collection
Completed NCT00902278 - Immune Responses Induced by Different Licensed Influenza Vaccines N/A
Completed NCT00346619 - Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults Phase 1
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Active, not recruiting NCT05534893 - Effect of Blueberries on Immunity and Response to Flu Vaccination N/A
Completed NCT05970887 - Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines Phase 4
Completed NCT05706350 - Plant Stanol Esters and Influenza Vaccination N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Completed NCT02933931 - Immune Durability After VSV-EBOV Vaccination
Recruiting NCT01289535 - Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years Phase 4
Active, not recruiting NCT02441426 - Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A